Cancer drugs: High price, uncertain value

BMJ (Online)

Volumn 359, Issue , 2017, Pages

  Cohen, Deborah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; PANITUMUMAB; PDL 3280A; POMALIDOMIDE; UNCLASSIFIED DRUG; VINFLUNINE;

ARTICLE; BLADDER CANCER; CANCER PATIENT; COLORECTAL CANCER; DRUG COST; HUMAN; MALIGNANT NEOPLASM; METASTATIC BREAST CANCER; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRESCRIPTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG CONTROL; ECONOMICS; EUROPE; LEGISLATION AND JURISPRUDENCE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; DRUG COSTS; EUROPE; HUMANS; TREATMENT OUTCOME;

EID: 85030648064     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j4543     Document Type: Article

References (18)

1. Davis C, Naci H, Gurpinar E, et al. Availability of evidence on overall survival and quality of life benefits of cancer drugs approved by the European Medicines Agency: Retrospective cohort study of drug approvals from 2009-2013. BMJ 2017;359:j4530.
2. European Society of Medical Oncology. Licensing and reimbursement discrepancies impact patient access to cancer treatment. Press release, 10 Sep 2017. http://www.esmo. org/Press-Office/Press-Releases/Licensing-and-Reimbursement-Discrepancies-Impact-Patient-Access-to-Cancer-Treatment)
3. European Medicines Agency. Assessment report for Vectibix. 2011. http://www.ema. europa.eu/docs/en-GB/document-library/EPAR---Assessment-Report---Variation/human/000741/WC500118765.pdf
4. Peeters M, Price TJ, Cervantes A, et al. Final results from a randomized phase 3 study of FOLFIRI panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014;359:107-16. doi:10.1093/annonc/mdt523 pmid:24356622.
5. European Ombudsman. Reply from the European Medicines Agency (EMA) to the Ombudsman's strategic inquiry OI/7/2017/KR into pre-submission activities organised by EMA. https://www.ombudsman.europa.eu/en/cases/correspondence.faces/en/83875/html. bookmark
6. EMA. Funding. http://www.ema.europa.eu/ema/index.jsp?curl=pages/about-us/general/general-content-000130.jsp&mid=WC0b01ac0580029336
7. Action on Bladder Cancer. Vinflunine for the treatment of transitional cell carcinoma of the urothelial tract. Letter to NICE, 14 Dec 2010. https://www.nice.org.uk/guidance/ta272/documents/transitional-cell-carcinoma-of-the-urothelial-tract-vinflunine-action-on-bladdercancer2
8. Fight Bladder Cancer. Current trials. http://fightbladdercancer.co.uk/research
9. EMA. Positive opinion on the change to the marketing authorisation for Vectibix (panitumumab). 2011. http://www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2011/06/WC500108022.pdf
10. NICE. Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal). 2011.https://www.nice.org.uk/guidance/ta240
11. Food and Drug Administration Center for Drug Evaluation and Research. Application number: 2040226Orig1s000 Administrative and Correspondence Documents. 2011; https://www.accessdata.fda.gov/drugsatfda-docs/nda/2013/204026Orig1s000Admincorres.pdf.
12. Food and Drug Administration. Supplement approval and fulfillment of postmarketing requirements. 2013. https://www.accessdata.fda.gov/drugsatfda-docs/appletter/2015/0204026Orig1s005, s006, s008ltr.pdf.
13. Elvidge S. NHS England cuts treatments from Cancer Drugs Fund. Pharmaceutical Journal 2015Sep 8. http://www.pharmaceutical-journal.com/news-and-analysis/nhs-england-cutstreatments-from-cancer-drugs-fund/20069298.article
14. Davis C, Lexchin J, Jefferson T, Gøtzsche P, McKee M. "Adaptive pathways" to drug authorisation: Adapting to industry?BMJ 2016;359:i4437. doi:10.1136/bmj.i4437 pmid: 27531201.
15. FDA. Questions and answers: Removing metastatic breast cancer as an indication from avastin's product labeling. 2011. https://www.fda.gov/NewsEvents/Newsroom/ucm280533.htm.
16. EMA. European Medicines Agency completes its review of Avastin used in breast cancer. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2010/12/news-detail-001166.jsp&mid=WC0b01ac058004d5c1
17. National Audit Office. Investigation into the Cancer Drugs Fund. 2015. https://www.nao. org.uk/wp-content/uploads/2015/09/Investigation-into-the-Cancer-Drugs-Fund1.pdf
18. Breast Cancer Care. Cancer Drugs Fund: Kadcyla stays but Avastin no longer available. 5 Nov 2015. https://www.breastcancercare.org.uk/about-us/news-blogs/news/cancerdrugs-fund-kadcyla-stays-avastin-no-longer-available